Preliminary recommendation by NICE not to include SCENESSE® for reimbursement by NHS England
21 December 2017 CLINUVEL PHARMACEUTICALS LTD today announced that the first draft...
Read More
CLINUVEL Newsletter - December 2017
07 December 2017 The CLINUVEL team is looking with much optimism and...
Read More
Lapse and Forfeit of Unlisted Conditional Performance Rights
05 December 2017 CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; XETRA-DAX: UR9; NASDAQ INTERNATIONAL...
Read More
Appendix 3Z - Final Director’s Interest Notice
05 December 2017 We (the entity) give ASX the following information under...
Read More
Results of Meeting
27 November 2017 In accordance with Listing Rule 3.13.2 and section 251AA...
Read More
Managing Director's AGM Presentation
27 November 2017 Today’s discussion outlines the CLINUVEL Board’s objectives to lead...
Read More
Chair's Address to the Annual General Meeting
28 November 2017 Coming from the background of an ethical pharmaceutical company...
Read More
Response to ASX Price Query
07 November 2018 Enclosed is the response of CLINUVEL PHARMACEUTICALS LTD in...
Read More
Appendix 4C
29 October 2017 CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; XETRA-DAX: UR9; NASDAQ INTERNATIONAL...
Read More
Notice of Annual General Meeting/Proxy Form
26 October 2017 This Explanatory Memorandum has been prepared for the Shareholders...
Read More
Appendix 4G
26 October 2017 This statement reports on the main corporate governance practices...
Read More
CLINUVEL Newsletter - October 2017
16 October 2017 I am addressing you during quite a turbulent period,...
Read More
CLINUVEL CONFIRMS AGM DATE
10 October 2017 CLINUVEL PHARMACEUTICALS LTD today announced it will hold its...
Read More
ELIE ISHAG TO RETIRE FROM CLINUVEL BOARD
04 October 2017 CLINUVEL PHARMACEUTICALS LTD today announced that Mr Elie Ishag...
Read More
CLINUVEL PROVIDES UPDATE ON SCENESSE® FDA FILING
19 September 2017 CLINUVEL PHARMACEUTICALS LTD today announced an update on its submission...
Read More